Rocket Pharmaceuticals, Inc. (RCKT) Stock Forecast
RCKT analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 3.86 / 5 from 14 analysts
- Price target
- $8.58 average of analyst targets
- Upside to target
- +293.5% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.39
- 52-week range
- $2.18 – $5.30
RCKT analyst ratings
14 analystsNumber of analysts at each rating.
RCKT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RCKT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.41 | −$0.43 | −$0.35 | −$0.45 | +10.3% | 5 |
| Current fiscal year (2026) | −$0.11 | −$0.20 | $0.08 | −$1.98 | +94.6% | 4 |
| Next fiscal year (2027) | −$1.30 | −$1.84 | −$0.12 | −$0.11 | −1,111.2% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RCKT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $181,820 | $0 | $2.0M | 0.0% | 11 |
| Current fiscal year (2026) | $1.1M | $0 | $5.0M | 0.0% | 12 |
| Next fiscal year (2027) | $11.2M | $0 | $29.3M | +915.6% | 12 |
RCKT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RCKT revenue: reported and forecast
RCKT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.41 | −$0.41 | −$0.41 | −$0.41 | −$0.41 | −2.2% | 2 up · 1 down |
| Current fiscal year (2026) | −$0.90 | −$0.90 | −$0.11 | −$0.11 | −$0.11 | −88.0% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.22 | −$1.22 | −$1.30 | −$1.30 | −$1.30 | +7.0% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RCKT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RCKT beat in 9 of 12.
What analysts expect from RCKT
14 analysts cover Rocket Pharmaceuticals; their consensus rating is buy (3.86 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.58, 293.5% above the latest close of $2.18. Analysts expect earnings of −$0.11 per share for 2026, +94.6% from a year earlier. For 2027 the average estimate is −$1.30 per share on revenue of $11.2 million. Rocket Pharmaceuticals beat the EPS estimate in 9 of the last 12 quarters.
Related: RCKT income statement, RCKT key metrics, RCKT chart. See the RCKT stock overview for the latest quote and news.
RCKT forecast FAQ
What is Rocket Pharmaceuticals's price target?
The average analyst price target for Rocket Pharmaceuticals is $8.58, 293.5% above the latest close of $2.18.
Is Rocket Pharmaceuticals a buy, hold or sell?
Of 14 analysts covering Rocket Pharmaceuticals, 6 rate it a strong buy, 1 a buy, 6 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Rocket Pharmaceuticals's EPS forecast?
Analysts forecast −$0.11 per share for 2026 (range −$0.20 to $0.08); for 2027 the estimate is −$1.30.
What is Rocket Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $1.1 million, growth of 0.0%; for 2027 it is $11.2 million.
When does Rocket Pharmaceuticals report earnings?
Rocket Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.39.
Does Rocket Pharmaceuticals usually beat earnings estimates?
Rocket Pharmaceuticals reported EPS at or above the analyst estimate in 9 of the last 12 quarters.